Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Trial Type:  Supportive care
Results 1-25 of 44 for your search:
Start Over
A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 471501, NCI-2016-01887, NCT02956122
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Status: Not yet active
Phase: Phase III
Type: Prevention, Supportive care, Treatment
Age: 2 to 25
Trial IDs: ACCL1633, NCI-2017-00208, COG-ACCL1633, NCT03057054
Baricitinib in Treating Chronic Graft Versus Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Supportive care
Age: 18 to 99
Trial IDs: 16-C-0094, NCI-2016-00773, NCT02759731
Pacritinib, Sirolimus, and Tacrolimus in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: MCC-18783, NCI-2017-00594, NCT02891603
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Relapsed Multiple Myeloma Undergoing Chemotherapy
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 11-373, NCI-2012-00821, NCT01484314
Palifermin with Leuprolide Acetate after Total-Body Irradiation Based Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 to 60
Trial IDs: 12-077, NCI-2012-02983, NCT01746849
Sotatercept in Increasing Bone Mineral Density in Patients with Multiple Myeloma with Complete or Very Good Partial Response after Previous Treatment
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: Over 18
Trial IDs: IUCRO-0428, NCI-2014-01967, 1408844060, ACE-011-MM-PI-0008, NCT02230917
Shortened-Duration of Immunosuppressant after Chemotherapy and Donor Stem Cell Transplant in Reducing Transplant Rejection in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: J15165, NCI-2015-02273, CIR00014686, IRB00080399, NCT02556931
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: GS-US-406-1840, NCI-2016-00628, 2015-004572-30, NCT02701634
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: Any age
Trial IDs: BMTCTN1501, NCI-2016-00996, 2U10HL069294-11, 5U24CA076518, NCT02806947
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
Status: Active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: CA204-185, NCI-2016-01231, 2016-000037-51, NCT02719613
Dietary Intervention in Preventing Acute Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Prevention, Supportive care
Age: 10 and over
Trial IDs: UMCC 2016.029, NCI-2016-01415, NCT02763033
Enterade in Reducing Side Effects from High-Dose Melphalan in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 16-329, NCI-2016-01562, NCT02919670
Obinutuzumab in Preventing Chronic Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: 16-256, NCI-2016-01860, NCT02867384
Ixazomib Citrate in Preventing Recurrent, Late Acute, or Chronic Graft Versus Host Disease after Donor Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: 16-076, NCI-2017-00538, NCT03082677
Broad-Spectrum Antibiotics in Treating Fever and Neutropenia in Patients Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 17-097, NCI-2017-00545, NCT03078010
Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients with Cancer Undergoing BEAM Conditioning Regimen before Stem Cell Transplant
Status: Not yet active
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: STUDY00016288, NCI-2017-00548, NCT03097588
High-Dose Trivalent Influenza Vaccine or Standard-Dose Quadrivalent Inactivated Influenza Vaccine in Treating Adult Stem Cell Transplant Recipients
Status: Not yet active
Phase: Phase II
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: VICC BMT 1733, NCI-2017-00466, NCT03179761
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: AIC316-03-II-01, NCI-2017-01156, NCT03073967
Isavuconazole after Donor Stem Cell Transplant in Preventing Invasive Fungal Infections in Patients with Hematologic Malignancies or Myeloproliferative Disorder
Status: Active
Phase: Phase II
Type: Prevention, Supportive care
Age: 18 and over
Trial IDs: 17-112, NCI-2017-01146, NCT03149055
Regulatory T-cell Depletion before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Status: Active
Phase: Phase I
Type: Supportive care, Treatment
Age: 21 to 70
Trial IDs: 10-551-B, NCI-2015-01660, NCT01526096
Start Over